Key Events This Week
20 Jul: Stock opens at Rs.1,223.30, up 1.03% despite flat Sensex
22 Jul: Q1 FY27 results reveal margin pressures and revenue decline
23 Jul: Stock hits 52-week low of Rs.1,080.05 with significant gap down
24 Jul: Technical indicators signal mildly bearish momentum amid continued price pressure
24 Jul: Week closes at Rs.1,152.60, down 4.81% for the week
20 July 2026: Positive Start Amid Flat Market
Dr Reddys Laboratories Ltd began the week on a relatively positive note, with the stock closing at Rs.1,223.30, up 1.03% from the previous close. This gain came despite the Sensex remaining virtually flat, closing at 36,504.94 with a negligible decline of 0.00%. The volume was moderate at 52,437 shares, indicating steady investor interest. This initial strength, however, was short-lived as the week progressed.
22 July 2026: Earnings Pressure Emerges
The company reported its Q1 FY27 results on 22 July, revealing mounting margin pressures amid a decline in revenue. The stock reacted negatively, closing at Rs.1,183.00, down 1.95% on the day, while the Sensex fell 0.88%. The volume surged to 165,968 shares, reflecting increased trading activity as investors digested the disappointing earnings. The results highlighted a significant fall in Profit Before Tax and Profit After Tax, signalling ongoing financial challenges.
23 July 2026: Sharp Gap Down and New 52-Week Low
On 23 July, Dr Reddys Laboratories Ltd opened with a pronounced gap down of 8.7%, hitting a new 52-week low of Rs.1,080.05. The stock closed at Rs.1,166.50, down 1.39% for the day, underperforming both its Pharmaceuticals & Biotechnology sector peers and the broader market. The intraday volatility was notably high at 64.86%, underscoring significant price swings and investor uncertainty. This day marked the culmination of a three-day downward trend, with the stock losing over 6% cumulatively. The Mojo Grade downgrade to Sell and deteriorating technical indicators contributed to the heightened selling pressure.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
24 July 2026: Mildly Bearish Technical Momentum
The stock closed the week at Rs.1,152.60, down 1.19% on 24 July, continuing the downward trend. Technical indicators signalled a shift to mildly bearish momentum, with weekly and monthly MACD and Bollinger Bands pointing to increased downside pressure. The Relative Strength Index remained neutral, offering no clear reversal signal. Daily moving averages showed some short-term support, but this was insufficient to offset the broader negative trend. The stock’s Mojo Score remained at 36.0, categorised as Sell, reflecting the cautious market sentiment.
Daily Price Comparison: Dr Reddys Laboratories Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-20 | Rs.1,223.30 | +1.03% | 36,504.94 | -0.00% |
| 2026-07-21 | Rs.1,206.55 | -1.37% | 36,518.28 | +0.04% |
| 2026-07-22 | Rs.1,183.00 | -1.95% | 36,196.43 | -0.88% |
| 2026-07-23 | Rs.1,166.50 | -1.39% | 35,944.66 | -0.70% |
| 2026-07-24 | Rs.1,152.60 | -1.19% | 35,829.46 | -0.32% |
Key Takeaways
1. Earnings and Margin Pressures: The Q1 FY27 results released midweek revealed significant margin contraction and revenue decline, which weighed heavily on investor sentiment and triggered a sharp sell-off.
2. Technical Weakness and Downgrade: The stock’s fall below all major moving averages and the downgrade to a Sell Mojo Grade intensified bearish momentum, culminating in a steep gap down and a 52-week low.
3. Relative Underperformance: Dr Reddys Laboratories Ltd underperformed the Sensex by a wide margin, falling 4.81% compared to the benchmark’s 1.85% decline, highlighting company-specific challenges amid broader market weakness.
4. Elevated Volatility: Intraday swings, particularly on 23 July, reflected heightened uncertainty and investor caution, with volatility reaching 64.86% during the session.
5. Mixed Technical Signals: While daily moving averages offered some short-term support, weekly and monthly indicators remained bearish, suggesting the stock may face continued pressure in the near term.
Considering Dr Reddys Laboratories Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this large-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Conclusion
Dr Reddys Laboratories Ltd’s performance during the week of 20 to 24 July 2026 was marked by a clear downward trajectory driven by disappointing quarterly results, technical deterioration, and a significant gap down to a 52-week low. The stock’s 4.81% weekly decline notably outpaced the Sensex’s 1.85% fall, underscoring company-specific challenges amid a cautious market environment. While some short-term technical support exists, the prevailing signals remain bearish, reflecting ongoing margin pressures and investor wariness. The downgrade to a Sell Mojo Grade further emphasises the need for caution as the stock navigates this difficult phase. Investors should closely monitor upcoming financial updates and technical developments to assess any potential shifts in momentum.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
